SD Biotechnologies KRX:217480KOSDAQ
에스디생명공학 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days1
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, SD Biotechnologies reported revenue of ₩6.3bn, down 19.3% year on year, and an operating loss of ₩1.4bn. SD Biotechnologies (에스디생명공학) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Sep 14 with 1 article. It was most often mentioned alongside Daewon Pharmaceutical.
SD Biotechnologies quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩6.3bn | -19.3% | −₩1.4bn | −₩875m |
| Q1 2026 | ₩6.1bn | -33.0% | −₩1.1bn | −₩1.2bn |
| Q4 2025 derived | ₩6.3bn | -4.2% | −₩1.6bn | −₩3.0bn |
| Q3 2025 | ₩6.9bn | -15.4% | −₩1.7bn | −₩1.9bn |
| Q2 2025 | ₩7.8bn | -19.5% | −₩1.9bn | −₩1.3bn |
| Q1 2025 | ₩9.1bn | -9.8% | −₩1.2bn | −₩1.3bn |
| Q4 2024 derived | ₩6.6bn | +84.8% | −₩3.5bn | −₩5.3bn |
| Q3 2024 | ₩8.1bn | -31.2% | −₩2.2bn | −₩3.8bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
SD Biotechnologies top stories 2 weeks, by number of outlets
- 1
